CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
LiverTarget develops innovative RNA-based therapies to treat obesity, diabetes, non-alcoholic fatty liver disease, and atherosclerosis. By creating targeted small interfering RNA and messenger RNA formulations using liver-targeting lipid nanoparticles, the project aims to improve treatment efficacy and safety for these…
RNA Therapeutics comprise a new rapidly expanding category of drugs including small interfering RNAs (siRNA) and messenger RNAs (mRNA) that have attracted tremendous interest recently due to their first in-class drug approvals and notable
success of the mRNA vaccines in the clinic.Obesity, diabetes, non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular disease (ASCVD), in turn, are highly prevalent devastating diseases of our times despite available
medicines, accounting f…
TAMPEREEN KORKEAKOULUSAATIO SR
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Milano
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Planegg
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Denmark, Odense M
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS
Greece, Athina
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
